ReviewVaccine2015
Chitosan-based mucosal adjuvants: Sunrise on the ocean.
Review in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 105 citations in OpenAlex.
- Breaking Biological Barriers: Engineering Nanocarriers for Efficient Drug and Gene Delivery through Nano-Bio Interfaces and Biophysical Design.Applied physics reviews · 2026Article
- Repurposing insulin for Alzheimer's disease treatment: intranasal delivery of a thermoresponsive nanocarrier-based insulin formulation to the brain.Drug delivery and translational research · 2026Article
- Correlations Between Rheology, In Situ Mucosal Retention and In Vivo Immunogenicity Reveal the Potential and Limitations of Mucoadhesive Excipients for Sublingual Vaccine Delivery.Pharmaceutics · 2025Article
- Prodrug nanosystem equipped with a sonosensitizer for combined chemotherapy and sonodynamic therapy of melanoma.Materials today. Bio · 2025Article
- Article
- Biodistribution and Adjuvant Effect of an Intranasal Vaccine Based on Chitosan Nanoparticles against Paracoccidioidomycosis.Journal of fungi (Basel, Switzerland) · 2023Article
- A Thermal and Enzymatic Dual-Stimuli Responsive DNA-Based Nanomachine for Controlled mRNA Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania Major.Molecules (Basel, Switzerland) · 2022Article
- Mucosal delivery of nanovaccine strategy against COVID-19 and its variants.Acta pharmaceutica Sinica. B · 2022Review
- Intranasal administration of immunogenic poly-epitope fromIranian journal of basic medical sciences · 2021Article
- Intranasal immunization with inactivated chlamydial elementary bodies formulated in VCG-chitosan nanoparticles induces robust immunity against intranasal Chlamydia psittaci challenge.Scientific reports · 2021Article
- Cord Blood-Based Approach to Assess Candidate Vaccine Adjuvants Designed for Neonates and Infants.Vaccines · 2021Review
- Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021Review
- Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.Cells · 2020Review
- Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines.International journal of biological macromolecules · 2020Review
- Green preparation of hydrogel particles-in-emulsions for simultaneous enhancement of humoral and cell-mediated immunity.Engineering in life sciences · 2020Article
- Carbohydrate Immune Adjuvants in Subunit Vaccines.Pharmaceutics · 2020Review
- Intranasal Vaccine Using P10 Peptide Complexed within Chitosan Polymeric Nanoparticles as Experimental Therapy for Paracoccidioidomycosis in Murine Model.Journal of fungi (Basel, Switzerland) · 2020Article
- Characteristics, Cryoprotection Evaluation and In Vitro Release of BSA-Loaded Chitosan Nanoparticles.Marine drugs · 2020Article
- Chitosan Derivatives and Their Application in Biomedicine.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal vaccination, which is shown to elicit systemic and mucosal immune responses, serves as a non-invasive and convenient alternative to parenteral administration, with stronger capability in combatting diseases at the site of entry. The exploration of potent mucosal adjuvants is emerging as a significant area, based on the continued necessity to amplify the immune responses to a wide array of antigens that are poorly immunogenic at the mucosal sites. As one of the inspirations from the ocean, chitosan-based mucosal adjuvants have been developed with unique advantages, such as, ability of mucosal adhesion, distinct trait of opening the junctions to allow the paracellular transport of antigen, good tolerability and biocompatibility, which guaranteed the great potential in capitalizing on their application in human clinical trials. In this review, the state of art of chitosan and its derivatives as mucosal adjuvants, including thermo-sensitive chitosan system as mucosal adjuvant that were newly developed by author's group, was described, as well as the clinical application perspective. After a brief introduction of mucosal adjuvants, chitosan and its derivatives as robust immune potentiator were discussed in detail and depth, in regard to the metabolism, safety profile, mode of actions and preclinical and clinical applications, which may shed light on the massive clinical application of chitosan as mucosal adjuvant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.